Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting

Presentations support proprietary suprachoroidal space delivery platform and programs

ALPHARETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple clinical poster presentations related to its suprachoroidal injection platform and programs were delivered at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting which took place May 1-7, 2021.

“The posters delivered at ARVO are increasingly important as we advance our CLS-AX clinical program and our New Drug Application for XIPERE which is under review by the U.S. Food and Drug Administration,” said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer. “The analyses demonstrate the utility of our proprietary suprachoroidal space (SCS) delivery platform to administer small molecules and gene therapy. The data also continues to validate suprachoroidal delivery as an office-based, repeatable form of administration for therapies for multiple retinal disorders.”

Suprachoroidal Space Delivery Platform

Title: Suprachoroidal injections across species via multimodal imaging

Lead Author: Allen Ho

Conclusions: This project compared suprachoroidal and intravitreal injections using diagnostic imaging and documented three important treatment attributes of suprachoroidal delivery: 1) acute opening of the suprachoroidal space; 2) circumferential, posterior spread of injectate in the suprachoroidal space; and 3) compartmentalization of injectate to posterior tissues away from anterior and corneal tissues. In contrast to intravitreal delivery, suprachoroidal drug delivery targets chorioretinal tissue layers, supporting the potential for more precise delivery to potentially enhance safety and efficacy.

Title: Safety of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders

Lead Author: Sumit Sharma

Conclusions: In this analysis, safety data from the day of the procedure was compiled from 626 patients in eight clinical trials where suprachoroidal injections were performed across three disease states, including non-infectious uveitis, diabetic macular edema, and retinal vein occlusion. Overall, across the eight clinical trials, the safety profile of suprachoroidal injections (SCI), either as monotherapy or in conjunction with intravitreal anti-VEGF injections, is broadly comparable to intravitreal anti-VEGF injections alone.